NASDAQ false 0001703647 0001703647 2024-06-17 2024-06-17

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 17, 2024

 

 

Korro Bio, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39062   47-2324450

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

One Kendall Square, Building 600-700, Suite 6-401

Cambridge, MA

   02139
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 468-1999

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common stock, par value $0.001 per share   KRRO   The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 17, 2024, Steve Colletti, Ph.D., notified Korro Bio, Inc. of his intent to resign as its Chief Scientific Officer effective August 2, 2024.

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    KORRO BIO, INC.
Date: June 21, 2024     By:  

/s/ Ram Aiyar

    Name:   Ram Aiyar
    Title:   President and Chief Executive Officer
v3.24.1.1.u2
Document and Entity Information
Jun. 17, 2024
Cover [Abstract]  
Security Exchange Name NASDAQ
Amendment Flag false
Entity Central Index Key 0001703647
Document Type 8-K
Document Period End Date Jun. 17, 2024
Entity Registrant Name Korro Bio, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39062
Entity Tax Identification Number 47-2324450
Entity Address, Address Line One One Kendall Square
Entity Address, Address Line Two Building 600-700
Entity Address, Address Line Three Suite 6-401
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02139
City Area Code (617)
Local Phone Number 468-1999
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common stock, par value $0.001 per share
Trading Symbol KRRO
Entity Emerging Growth Company true
Entity Ex Transition Period false
Frequency Therapeutics (NASDAQ:FREQ)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas Frequency Therapeutics.
Frequency Therapeutics (NASDAQ:FREQ)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas Frequency Therapeutics.